• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in gastroenterology. >Ustekinumab for the treatment of Crohn's disease: can it find its niche?
【24h】

Ustekinumab for the treatment of Crohn's disease: can it find its niche?

机译：Ustekinumab用于治疗克罗恩病：能否找到合适的市场？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Crohn's disease is an immune-mediated disease that results in panenteric chronic inflammation in genetically predisposed individuals exposed to an appropriate environment. The past two decades have witnessed the emergence of an important class of drugs known as anti-tumour necrosis factor (TNF) agents in the treatment of Crohn's disease. Unfortunately, the utility of these agents have been hampered by primary and secondary nonresponse in a significant proportion of patients. Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin (IL) 12 and 23, is a novel pharmacotherapy for this patient cohort that offers an out-of-class option. It is approved for use in psoriasis and psoriatic arthritis, and has now been evaluated in phase II trials for moderate-to-severe Crohn's disease. We here review the published literature and describe a potential clinical role for its use in this disease cohort.
机译：克罗恩氏病是一种免疫介导的疾病，会导致暴露于适当环境中的遗传易感人群发生全肠性慢性炎症。在过去的二十年中，见证了一种用于治疗克罗恩氏病的重要类药物，即抗肿瘤坏死因子（TNF）药物的出现。不幸的是，在相当大比例的患者中，这些药物的效用受到主要和次要无反应的阻碍。 Ustekinumab是针对白介素（IL）12和23 p40亚基的单克隆抗体，是针对该患者队列的新型药物疗法，提供了一流的选择。它被批准用于牛皮癣和银屑病关节炎，现已在中至重度克罗恩病的II期试验中进行了评估。我们在这里回顾已发表的文献，并描述其在该疾病队列中的潜在临床作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号